IQVIA Holdings Inc. $IQV Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 65.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 499,987 shares of the medical research company’s stock after purchasing an additional 198,214 shares during the quarter. BNP Paribas Financial Markets’ holdings in IQVIA were worth $112,702,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Claret Asset Management Corp boosted its holdings in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after acquiring an additional 49 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. raised its stake in shares of IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 58 shares in the last quarter. Brookstone Capital Management raised its stake in shares of IQVIA by 2.2% during the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares in the last quarter. Private Advisor Group LLC raised its stake in shares of IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares in the last quarter. Finally, Keybank National Association OH raised its stake in shares of IQVIA by 0.7% during the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after purchasing an additional 67 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IQV shares. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, April 19th. Royal Bank Of Canada started coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. Citigroup cut their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Buy” and an average price target of $225.69.

IQVIA Price Performance

Shares of IQVIA stock opened at $182.03 on Monday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company’s 50-day moving average price is $170.34 and its two-hundred day moving average price is $196.05. IQVIA Holdings Inc. has a 52 week low of $136.41 and a 52 week high of $247.04. The stock has a market cap of $30.38 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 1.74 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s management believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.